Abstract:Vascular endothelial growth factor (VEGF) and the receptor VEGFR-2 (KDR) are the major components of angiogenesis signaling pathway and proven targets for the treatment of several solid tumors. However, recent studies have revealed that agents targeting VEGF/VEGFR-2 can promote tumor invasiveness and distant metastasis. These findings suggest that any future antiangiogenic therapies should be combined with mechanisms targeting cancer invasiveness and metastasis. Hepatocyte growth factor (HGF) receptor c-Met (HGFR) is a receptor tyrosine kinase considered critically involved in the control of cancer development, invasion, and metastasis. Studies have suggested that Inhibition of c-Met can not only reduce c-Met dependent tumor growth, but also decrease tumor invasion and metastasis. Thus, it is conceivable that targeting both c-Met and VEGFR-2 simultaneously will inhibit tumor growth and, at the same time, prevent tumor from invasion and metastasis through the following mechanisms: 1) synergy between VEGFR-2 and c-Met inhibition in antiangiogenesis; 2) inhibition of c-Met driven tumor growth; 3) disruption of c-Met mediated tumor invasion and metastasis. Compounds including ASP-08001 and 08126 were identified as small molecule, ATP competitive inhibitors of both c-Met and VEGFR-2 kinases through biochemical assays. In cellular studies, these compounds inhibited potently the activating phosphorylation of cytoplasmic domains of both kinases as well as c-Met and VEGFR-2 driven phenotypes such as cell proliferation, invasion, and angiogenesis. In addition, pharmacodynamic studies revealed that a single oral dose of a compound was able to inhibit the phosphorylation of cytoplasmic domains of both targeted and downstream kinases in tumor xenografts for up to 16 hours. The level of kinase inhibition in tumor tissues was well correlated with the plasma concentration of the compound inversely indicative of a proof of mechanism of actions. The antitumor efficacies of the compounds were demonstrated in xenograft tumor models of several human cancers including NSCLC, breast, gastric, and prostate cancers. Complete tumor growth arrest or even regression induced by oral dosing (50 or 100 mg/kg, q.d.) of the compounds was observed. Furthermore, pharmacokinetic studies suggested a promising drug-like PK profile for these compounds. Finally, single-dose acute toxicity studies of the compounds could not find a lethal dose in mice even though dosing had reached 5000mg/kg, suggesting a therapeutic index of greater than 50 and a promising safety profile. In summary, we reported here the discovery of small molecule, ATP-competitive, c-Met and VEGFR-2 inhibitors such as ASP-08001 and −08126 that have demonstrated strong potency in target inhibition and desired efficacies against a variety of human tumor models suggesting strong therapeutic potentials against human cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3613.

[Intraperitoneal injection of human-derived anti-c-Met single-chain antibody inhibits the growth of transplanted tumours in A549 lung adenocarcinoma-loaded mice]

A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts

Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models

Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C.

Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

Near-infrared fluorescence-guided resection of micrometastases derived from esophageal squamous cell carcinoma using a c-Met-targeted probe in a preclinical xenograft model

c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549

THE EFFECT OF SELECTIVE C-MET INHIBITOR ON HCC IN THE MET-ACTIVE, β-CATENIN MUTATED MOUSE MODEL.

Anti-c-MET Fab-Grb2-Gab1 Fusion Protein-Mediated Interference of c-MET Signaling Pathway Induces Methuosis in Tumor Cells

The effects of anti-lung cancer in nude mice by a fully human single-chain antibody against associated antigen Ts7TMR between A549 cells and Trichinella spiralis

Study of the mechanism of anti-tumor effect of Metformin-enhanced radiotherapy in CT26WT cell lines or mouse models with transplanted tumors

Study on the Inhibitory Effect of Small Tripeptide CMS024 on Tumor Growth and Metastasis in Nude Mice Model of Human Hepatocellular Carcinoma Metastasis

The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model

[The Effect of Antibody Against Vascular Endothelial Growth Factor (VEGF) on Tumor Metastasis].

BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1

Supplementary Figure 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Abstract 2615: Preclinical development of a next generation antibody drug conjugate (ADC) targeting cMET for treatment of solid tumors

Supplementary Figure 2 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Supplementary Figure 3 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Abstract 3613: Dual inhibitors against receptor tyrosine kinases c-Met and VEGFR-2 as efficacious antitumor agents in mouse xenograft tumor models